Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

Uterine artery embolization: BioSphere Medical's Embosphere tris-acryl gelatin microspheresare more effective in blocking blood flow to benign uterine fibroids than Boston Scientific's Contour SE polyvinyl alcohol microspheres, according to results of a study led by Gary P. Siskin, M.D., Albany Medical Center, published in the January Journal of Vascular and Interventional Radiology. In the 53-patient randomized study, co-funded by Boston Scientific and BioSphere, patients treated with Contour SE had a 29.6% treatment failure rate and 66.7% total success rate (100% occlusion of the arteries feeding the tumor), compared to a 3.8% failure rate and 92.3% success rate for Embosphere. Embosphere, already the market leader, "should be the preferred agent for UAE at this time," the authors conclude
Advertisement

Related Content

Olympic Cool-Cap approval
Advertisement
UsernamePublicRestriction

Register

MT025683

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel